About 30% of people with major depressive disorder fail to respond to at least two adequate antidepressant trials, which defines treatment resistant depression. In neurobiology studies, prefrontal cortex hypoactivity shows up on fMRI in about 70% of TRD cases, linking resistance to measurable brain function. These figures shift the focus from prevalence alone to what happens when one treatment after another does not work.
Key Takeaways
- BDNF Met66 allele frequency 30% higher in TRD vs responders
- TRD patients have 2.5 times higher suicide attempt rates than non-TRD MDD
- Approximately 30% of patients with major depressive disorder (MDD) fail to respond to at least two adequate antidepressant trials, defining treatment-resistant depression (TRD)
- Early age of MDD onset (<20 years) increases TRD risk by 2.5-fold
- Esketamine nasal spray achieves 70.8% response rate at week 4 in TRD (TRANSFORM-2 trial)
About a third of people with depression do not respond to standard treatments, highlighting the need for alternatives.
Related reading
01 · Category
Neurobiology24 stats
01
BDNF Met66 allele frequency 30% higher in TRD vs responders
02
Hippocampal volume reduction 15-20% in TRD patients
03
Elevated CRP levels (>3mg/L) in 45% of TRD cases
04
HPA axis hyperactivity (cortisol >20 mcg/dL) in 60% TRD
05
SLC6A4 short allele carriers 2x TRD risk under stress
06
Prefrontal cortex hypoactivity on fMRI in 70% TRD
07
Glutamate dysregulation (elevated CSF glutamate) in 50% TRD
08
IL-6 plasma levels 2-fold higher in TRD
09
Amygdala hyperconnectivity correlates with TRD severity (r=0.45)
10
FKBP5 rs1360780 polymorphism OR 1.5 for TRD
11
Reduced neuroplasticity markers (BDNF <15 ng/mL) in 55% TRD
12
Dopamine D2 receptor density decreased 20% in TRD striatum
13
TNF-alpha elevation (>10 pg/mL) predicts poor response 70% accuracy
14
Default mode network (DMN) hyperconnectivity in TRD fMRI
15
COMT Val158Met Val/Val genotype 1.6 OR for TRD
16
White matter hyperintensities 2x prevalent in late-life TRD
17
Serotonin transporter binding reduced 25% in TRD insula PET
18
Microglial activation (TSPO binding) elevated in 40% TRD
19
HTR2A T102C polymorphism increases TRD susceptibility OR 1.4
20
Thalamic glutamate/GABA ratio >1.2 predicts TRD (AUC 0.78)
21
Astrocytic dysfunction (S100B >0.5 ug/L) in TRD CSF
22
ACC gray matter volume 12% smaller in TRD
23
CLOCK gene 3111T/C variant OR 1.7 for TRD chronotype mismatch
24
Oxidative stress markers (8-OHdG) 1.8x higher in TRD
Interpretation
Neurobiology Interpretation
From these statistics, it seems your treatment-resistant depression is not merely a mood disorder but a full-blown, multi-system biological coup d'état, where your genes, immune system, and brain chemistry have formed a rather stubborn anti-recovery coalition.
02 · Category
Outcomes25 stats
01
TRD patients have 2.5 times higher suicide attempt rates than non-TRD MDD
02
5-year remission rate in TRD is only 20-30%
03
TRD mortality risk is 1.6-2.0 times higher due to suicide and comorbidities
04
Functional disability in TRD is 50% higher (SF-36 scores)
05
Healthcare costs for TRD patients are 4-6 times higher than responders
06
TRD relapse rate within 1 year post-remission is 60-70%
07
Unemployment in TRD reaches 40-50%
08
TRD patients lose 2-3 times more workdays annually
09
Quality-adjusted life years (QALYs) lost in TRD: 0.25 per year
10
Suicide completion rate in TRD 15%, vs 2% in responder MDD
11
10-year chronicity rate in TRD exceeds 50%
12
Hospitalization rates 3-fold higher in TRD (per 100 patient-years)
13
Cognitive impairment persists in 70% of remitted TRD patients
14
Cardiovascular comorbidity risk 2-fold in TRD
15
TRD survival curve shows 20% excess mortality at 5 years
16
Social functioning scores (SDS) 40% lower in TRD
17
Divorce rates 1.8 times higher in TRD marriages
18
TRD patients have 30% lower treatment adherence long-term
19
MADRS score reduction sustained <1 year in 55% of ECT remitters
20
TRD disability-adjusted life years (DALYs) 2.5x MDD average
21
2-year response durability after ketamine only 20-30%
22
TRD remission predicts 50% reduction in suicide risk
23
Economic burden of TRD $19-29 billion annually in US
24
TRD patients 4x more likely to attempt suicide post-hospitalization
25
Long-term VNS response plateaus at 45% after 5 years
Interpretation
Outcomes Interpretation
The sheer statistical weight of treatment-resistant depression paints a grim portrait of a condition not merely lingering in the mind, but actively dismantling a life from every angle—health, finances, work, and relationships—with a lethality that demands urgent and innovative care.
03 · Category
Prevalence30 stats
01
Approximately 30% of patients with major depressive disorder (MDD) fail to respond to at least two adequate antidepressant trials, defining treatment-resistant depression (TRD)
02
In the United States, TRD affects about 3 million adults annually, representing 10-30% of all MDD cases
03
Lifetime prevalence of TRD among MDD patients is estimated at 15-33%
04
TRD prevalence in primary care settings ranges from 10-20% of depressed patients
05
Globally, TRD accounts for 20-30% of MDD cases, with higher rates in severe depression
06
In Europe, TRD prevalence is around 20% in community samples of MDD
07
Among veterans with MDD, TRD rates reach 40%
08
Pediatric TRD affects 10-20% of adolescent MDD cases
09
TRD incidence increases with episode chronicity, up to 50% after 3 failed treatments
10
In outpatient psychiatry, 25-35% of MDD patients meet TRD criteria
11
TRD prevalence is 29% in STAR*D study cohort of 4,041 patients
12
Women have a 1.5-2 times higher TRD risk than men in MDD populations
13
TRD rates are 35% higher in bipolar depression vs unipolar MDD
14
In elderly MDD patients (>65 years), TRD prevalence is 25-40%
15
TRD affects 12-20% of first-episode MDD but rises to 40% in recurrent cases
16
Urban populations show 5-10% higher TRD prevalence than rural
17
During COVID-19, TRD rates in MDD increased by 15%
18
TRD prevalence in low-income groups is 1.8 times higher
19
In schizophrenia comorbid MDD, TRD reaches 50%
20
TRD accounts for 50% of long-term psychiatric hospitalizations in depression
21
Hispanic MDD patients have 20% higher TRD rates
22
TRD prevalence peaks at 30% in midlife (40-59 years)
23
In primary care, 15% of screened depression cases are TRD
24
TRD in perinatal depression affects 14-23% of cases
25
African American MDD patients show 25% TRD prevalence vs 18% in Caucasians
26
TRD rates are 28% in treatment-seeking MDD samples worldwide
27
Chronic pain comorbid MDD has 40% TRD rate
28
TRD prevalence in adolescents is 12%, rising to 30% by adulthood
29
In Canada, TRD affects 1 in 5 MDD patients
30
TRD represents 30% of total depression-related disability-adjusted life years (DALYs)
Interpretation
Prevalence Interpretation
A stubborn third of depression refuses to surrender to the first lines of defense, making the battle against it not an exception but a tragically common chapter in the story of mental illness.
More related reading
04 · Category
Risk Factors27 stats
01
Early age of MDD onset (<20 years) increases TRD risk by 2.5-fold
02
Female gender confers 1.6 odds ratio (OR) for TRD in MDD cohorts
03
Comorbid anxiety disorders raise TRD risk by 1.8 OR
04
Childhood trauma history triples TRD likelihood (OR 3.1)
05
Obesity (BMI >30) associated with 1.4 OR for TRD
06
Recurrent MDD episodes (>3) predict TRD with OR 2.2
07
Substance use disorders comorbid increase TRD risk by 2.0 OR
08
Chronic medical illness (e.g., diabetes) elevates TRD OR to 1.7
09
Family history of MDD doubles TRD risk (OR 2.1)
10
Hypothyroidism untreated increases TRD susceptibility by 1.9 OR
11
Smoking status correlates with 1.5 OR for TRD development
12
Bipolar spectrum features predict TRD with sensitivity 65%
13
Low socioeconomic status raises TRD OR to 1.6
14
Sleep disturbances at baseline predict TRD (OR 2.3)
15
Inflammation markers (CRP >3mg/L) associate with 2.4 OR for TRD
16
Genetic variants in FKBP5 gene increase TRD risk by 1.8 OR
17
Poor adherence to first antidepressant predicts TRD (OR 3.5)
18
Psychotic features in MDD elevate TRD risk 2.7-fold
19
High baseline depression severity (MADRS >30) OR 2.0 for TRD
20
Antidepressant monotherapy failure in first episode OR 1.9
21
Comorbid PTSD increases TRD OR to 2.6
22
Age <25 at onset OR 1.7 for TRD
23
Melancholic subtype MDD has 1.5 OR for TRD
24
Vitamin D deficiency (<20 ng/mL) associates with OR 1.4
25
Late-life MDD onset reduces TRD risk (OR 0.7)
26
SSRI non-response predicts TCA non-response (OR 2.1)
27
Remission after two trials is 25%, failure defines TRD per APA criteria
Interpretation
Risk Factors Interpretation
Depression's resistance is a haunting collaboration where genetics hands you a loaded gun, trauma pulls the trigger, and modern medicine sometimes forgets to check if the safety is on.
05 · Category
Treatment Efficacy27 stats
01
Esketamine nasal spray achieves 70.8% response rate at week 4 in TRD (TRANSFORM-2 trial)
02
Ketamine infusion yields 64% response rate within 24 hours in TRD
03
ECT remission rates 50-60% in severe TRD cases
04
Augmentation with atypical antipsychotics (aripiprazole) 25% remission boost
05
TMS response rate 50-55% in medication-resistant MDD
06
Psilocybin-assisted therapy shows 71% response in TRD (12-week follow-up)
07
Bupropion augmentation increases remission by 20% in SSRI non-responders
08
Lithium augmentation achieves 40-60% response in TRD
09
Vagus nerve stimulation (VNS) long-term remission 40% after 2 years
10
Pramipexole adjunctive therapy 60% response rate in bipolar TRD
11
MAOI switch yields 50% response in TCA/SSRI failures
12
CBT specifically for TRD improves response by 30% over TAU
13
Brexpiprazole augmentation 29.2% remission vs 10.6% placebo
14
Deep brain stimulation (DBS) 60-90% acute response in refractory TRD
15
Mirtazapine augmentation 40% response rate
16
rTMS at 10Hz protocol 42% remission rate
17
Ketamine 0.5 mg/kg IV 72% response at day 1, durability 33% at week 2
18
SCID augmentation with celecoxib 50% superior response
19
Psilocybin 25mg single dose 29% remission at 3 weeks
20
Lamotrigine adjunct 52% response vs 28% placebo
21
ECT bilateral 65% remission vs 45% unilateral
22
D-cycloserine augmentation of CBT 55% response boost
23
Vortioxetine switch 40% response in SSRI/SNRI failures
24
Magnetic seizure therapy (MST) 60% response with less cognitive side effects
25
Venlafaxine high-dose (375mg) 55% remission in level 2 STAR*D
26
Esketamine + oral AD 52.3% response vs 30.9% placebo (SUSTAIN-2)
27
Mindfulness-based cognitive therapy (MBCT) 44% relapse prevention in TRD
Interpretation
Treatment Efficacy Interpretation
The statistics paint a clear, albeit complex, battlefield: from the rapid fire of ketamine to the steady siege of therapies like VNS, overcoming treatment-resistant depression demands a strategic arsenal, not a single silver bullet.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Stefan Wendt. (2026, February 13). Treatment Resistant Depression Statistics. Gitnux. https://gitnux.org/treatment-resistant-depression-statistics
MLA
Stefan Wendt. "Treatment Resistant Depression Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/treatment-resistant-depression-statistics.
Chicago
Stefan Wendt. 2026. "Treatment Resistant Depression Statistics." Gitnux. https://gitnux.org/treatment-resistant-depression-statistics.
Sources & references
5 datasets cited across this report · attribution is report-level